Reportlinker Adds the Diabetes Device Market Outlook to 2016

Thursday, May 26, 2011 General News
Email Print This Page Comment
Font : A-A+

NEW YORK, May 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The

Diabetes Device Market Outlook to 2016

http://www.reportlinker.com/p0511988/The-Diabetes-Device-Market-Outlook-to-2016.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

The diabetes devices market was worth

$13.9bn in 2010 and with continued innovation and the increasing prevalence of this disease is poised for continued strong growth through to 2016.

This report gives coverage of the diabetes device market which incorporates both diagnostic and insulin delivery devices. Epidemiology of this disease is forecast to 2030 and the various market segments of the market are forecast through to 2016. The report includes detailed company profiles of the established key emerging companies. The regulatory environment and other key events are assessed.

Scope of this research

• Identify the market potential of the diabetes device market and the various diabetes device segments.

• Gain a quick and comprehensive understanding of the innovations shaping the diabetes device market.

• Identify the key innovations being developed by both emerging and established players and assess their potential.

• Benchmark performance in terms of revenue growth and product launch capabilities against the leading diabetes device companies.

• Learn from the strategies of leading diabetes device companies to target future growth areas, avoid their mistakes, and replicate their successes

Research and analysis highlights

The global diabetes device market is projected to reach $19.6bn by 2016, growing at a CAGR of 5.9%. Continuous glucose monitoring systems will emerge as the fastest growing market segment over this period as innovative systems with improved accuracy are introduced.

The market for insulin pen devices is projected to grow at a CAGR of 13% to 2016 driven by the rapid uptake of pre-filled insulin pens and increased penetration of insulin pens in the US, where these devices are underutilized as compared to Europe.

The market is very concentrated among the leading players. The top three companies controlled more than 50% of the market. Of the top five companies, all except for Bayer have utilized acquisitions to get access to innovative technologies. The emergence of several innovative, specialist companies has challenged the dominance of the leading players.

Key reasons to purchase this research

• Which will be the largest growth opportunities in the diabetes device market?

• Which companies are leading the various segments of the diabetes devices market?

• What are the new advances in diabetes devices and which of them offer the most significant potential in the future?

• How have the leading companies established their market leading positions in the various segments of the diabetes devices market?

• How have the leading companies in the diabetes device market performed financially over the last three years?

TABLE OF CONTENTS

About Business Insights 2

Disclaimer 2

Executive Summary 10

Overview of the diabetes devices market 10

Segmentation of the diabetes device market 11

Innovations in the diabetes device market 11

Key players in the diabetes device market 12

Developments in the diabetes device market 13

Chapter 1 Overview of the diabetes devices market 15

Summary 15

Introduction 16

Type-1 diabetes 16

Type-2 diabetes 17

Pre-gestational diabetes 17

Gestational diabetes mellitus (GDM) 18

Epidemiology 18

Economic burden of diabetes 22

Market size of the global diabetes devices 25

Historical market size of global diabetes devices 25

Forecast market size of global diabetes devices 25

Drivers of the global diabetes devices market 26

Increase in the prevalence of diabetes 26

Increase in the awareness of diabetes 27

Demand for regular monitoring of glucose 27

Demand for tight regulation of insulin levels in patients 27

Increase in the usage of self administered and patient convenient devices 28

Use of new devices as a strategy for differentiation and life cycle management 28

Impending patent expiries of insulin products and the growth of the biosimilars market 28

Resistors of the global diabetes devices market 29

Low compliance of glucose monitoring and treatment 29

Development of oral insulin products 29

Lack of reimbursement for new devices 29

High failure and recall rates for insulin pumps 30

Chapter 2 Segmentation of the diabetes device market 31

Summary 31

Glucose monitoring devices 32

Regular glucose monitoring devices 32

Working principle of a glucometer 33

Historical market size of regular glucose monitoring devices 33

Forecasts for regular glucose monitoring devices 35

Key companies and products 36

Continuous glucose monitoring (CGM) devices 37

Components of a CGM device 38

Historical market size of CGM devices 40

Forecasts for CGM devices 41

Reimbursement scenario for CGM devices in the US 41

Key companies and products 42

Insulin delivery devices 43

Insulin pumps 44

Components of an insulin pump 44

Historical market size of insulin infusion pumps 45

Forecasts for insulin infusion pumps 46

Key companies and products 47

Insulin pens 50

Components of an insulin pen 51

Historical market size of insulin pens 52

Forecasts for insulin pens 54

Key companies and products 55

Insulin syringes 57

Components of an insulin syringe 57

Historical market size of insulin syringes 59

Forecasts for insulin syringes 59

Key companies and products 60

Inhaled insulin devices - case study on Exubera 60

History of development of Exubera 61

Reasons for failure 61

The cost of failure 63

Conclusion 64

Current inhaled insulin products under development 64

Chapter 3 Innovations in the diabetes device market 66

Summary 66

Introduction 67

Advances in glucose monitoring devices 67

Regular glucose monitoring 68

Sanofi-Aventis 68

Mendor 68

Non-invasive glucose monitoring 68

Eyesense 69

Freedom Meditech 70

Calisto Medical 70

Diramed Technology 71

Integrity Applications 71

Glucon 73

GlucoLight 73

Glumetrics 74

Diabetes screening 75

VeraLight 75

Neurometrix 76

Eyetel Imaging 77

Advances in insulin delivery devices 78

Insulin pumps 78

Insulet 79

Medingo (acquired by Roche) 80

Cellnovo 81

MedSolve Technologies 82

Debiotech 83

Spring Health Solutions 83

Valeritas 86

CeQur 87

Calibra Medical 87

Insulin pens 88

Novo Nordisk 88

Eli Lilly 89

Sanofi-Aventis 89

Ypsomed 90

Artificial pancreas – closed loop systems 90

Medtronic 90

Animas, Dexcom, and the Juvenile Diabetes Research Foundation (JDRF) 91

Boston University and Massachusetts General Hospital 91

Institute of Metabolic Science at the University of Cambridge 91

Chapter 4 Key players in the diabetes device market 93

Summary 93

Introduction 94

Leading players 94

Roche 97

Company overview 97

Financial performance 98

Key segments and product portfolio 98

Growth strategies 98

Johnson & Johnson (J&J) 99

Company overview 99

Financial performance 100

Key segments and product portfolio 100

Growth strategies 100

Bayer 101

Company overview 101

Financial performance 101

Key segments and product portfolio 102

Growth strategies 102

Abbott 103

Company overview 103

Financial performance 103

Key segments and product portfolio 104

Growth strategies 104

Medtronic 105

Company overview 105

Financial performance 105

Key segments and product portfolio 105

Growth strategies 106

Becton Dickinson (BD) 107

Company overview 107

Financial performance 107

Key segments and product portfolio 107

Growth strategies 108

Ypsomed 108

Company overview 108

Financial performance 108

Key segments and product portfolio 109

Growth strategies 110

Insulet 111

Company overview 111

Key segments and product portfolio 111

Financial performance 111

Growth strategies 112

DexCom 112

Company overview 112

Key segments and product portfolio 113

Financial performance 113

Growth strategies 113

Emerging players and OEMs 114

Agamatrix 115

Taidoc 115

EPS Biotechnology 116

Tyson Bioresearch 116

Bionime 116

Chapter 5 Developments in the diabetes device market 118

Summary 118

Introduction 119

Regulatory and market developments impacting the market 119

US FDA looking to improve standards of accuracy for glucose meters 119

Stricter regulatory requirements for infusion pumps from the US FDA 120

Changes in PMN pathway 120

Comparative effectiveness research (CER) 121

Medical device excise tax 122

Mergers and acquisitions 122

Alliances and partnerships 124

New product approvals 127

Appendix 129

Scope 129

Methodology 129

Glossary/Abbreviations 130

References 133

Table of figures

Figure 1: Working reaction of a glucometer 33

Figure 2: Global regular glucose monitoring devices market size ($bn), 2005–10 34

Figure 3: Forecast global market size of regular glucose monitoring devices ($bn), 2010–16 35

Figure 4: Leading players' share of the regular glucose monitoring device market, 2010 36

Figure 5: Components of a CGM device 39

Figure 6: Global CGM devices market size ($bn),, 2005–10 40

Figure 7: Forecast global market size of CGM devices ($bn), 2010–16 41

Figure 8: Leading players' share of the CGM device market, 2010 42

Figure 9: Block diagram of an insulin infusion pump 45

Figure 10: Global regular insulin infusion pumps market size ($bn), 2005–10 46

Figure 11: Forecast global market size of insulin infusion pumps ($bn), 2010–16 47

Figure 12: Leading players' share of the insulin infusion pump market, 2010 48

Figure 13: Components of a typical insulin pen 51

Figure 14: Global insulin pen market size ($bn), 2005–10 52

Figure 15: Forecast global market size of insulin pens ($bn), 2010–16 54

Figure 16: Leading players' share of the insulin pens market, 2009 55

Figure 17: Components of a typical insulin syringe 58

Figure 18: Global insulin syringe market size ($bn), 2005–10 59

Figure 19: Forecast global market size of insulin syringes ($bn), 2010–16 60

Figure 20: Dreamboat Inhaler device for Afrezza 65

Figure 21: Components of the GlucoTrack device 72

Figure 22: The Sentris-100 device 74

Figure 23: Scout DS diabetes screening system 76

Figure 24: Flow chart for the EyeTel Retinal Imaging Telemetry System 77

Figure 25: Patch pumps under various stages of development 79

Figure 26: OmniPod Insulin Management System 80

Figure 27: Solo MicroPump 81

Figure 28: Cellnovo insulin pump 82

Figure 29: JewelPUMP 83

Figure 30: Components of the ADI Insulin Pump 85

Figure 31: V-Go disposable insulin delivery device 86

Figure 32: CeQur insulin infuser 87

Figure 33: Finesse insulin patch-pen 88

Figure 34: Leading diabetes device companies by product approvals, US, 2005–2010 127

Figure 35: Leading device approvals by category, US, 2005–2010 128

Table of tables

Table 1: Epidemiology of diabetes by region, 2010–2030 19

Table 2: Top 20 countries by diabetes burden in 2030 20

Table 3: Incidence and prevalence of Type-1 diabetes in 0–14 year age group, 2010 21

Table 4: Healthcare expenditure for diabetes by region, 2010–2030 23

Table 5: Top 20 countries by healthcare expenditure on diabetes in 2030 24

Table 6: Global segmental market size of diabetes devices ($m), 2005–10 25

Table 7: Forecast global segmental market size of diabetes devices, ($m), 2010–16 26

Table 8: Recommendations for SMBG frequency 32

Table 9: Key regular glucose monitoring devices 37

Table 10: Key marketed CGM devices 43

Table 11: Key insulin pump devices 49

Table 12: Global insulin pen market size ($bn) by segment, 2005–10 53

Table 13: Forecast global market size ($bn) of insulin pens by segment, 2010–16 55

Table 14: Demand for prefilled pens across leading brands (million units), 2009 56

Table 15: Market shares of leading companies in the global diabetes device market, 2009 95

Table 16: Global diabetes device revenues of leading companies, ($m), 2007–2009 96

Table 17: Presence of leading players in the various diabetes device segments 97

Table 18: Roche diabetes devices revenue performance ($m), 2005–2010 98

Table 19: J&J diabetes devices revenue performance ($m), 2005–2009 100

Table 20: Bayer diabetes devices revenue performance ($m), 2005–2010 102

Table 21: Abbott diabetes devices revenue performance ($m), 2005–2010 104

Table 22: Medtronic diabetes devices revenue performance ($m), 2005–2010 105

Table 23: BD diabetes devices revenue performance ($m), 2005–2010 107

Table 24: Ypsomed diabetes devices revenue performance ($m), 2008–2010 109

Table 25: Insulet diabetes devices revenue performance ($m), 2005–2010 112

Table 26: Dexcom diabetes devices revenue performance ($m), 2007–2010 113

Table 27: Key acquisitions in the diabetes devices market, 2000–2010 123

Table 28: Partnerships in the global diabetes device market, 2007–2011 125

Table 29: Partnerships in the global diabetes device market, 2007–2011 (continued) 126

To order this report:

Pathology Industry: The Diabetes Device Market Outlook to 2016

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook